Allergy immunotherapy is the only casual treatment to prevent allergy caused by food, grass pollen, dust, and bee venom among other causes.
Increasing cases of allergies is expected to witness significant growth of the market over the forecast period. For instance, according to the International Study of Asthma and Allergies in Childhood (ISAAC) 2016, around 22.1% children aged between 13 to 14 years are affected due to pollen allergy (hay fever) at global level.
Hence, increasing cases of allergies is expected to increase the demand of allergy immunotherapy.
The global allergy immunotherapy market is estimated to be valued at US$ 2,116.0 million in 2022 and expected to exhibit a CAGR of 9.3% over the forecast period (2022-2030).
Figure 1. Global Allergy Immunotherapy Market Share (%) in Terms of Value, by Region, 2022
The rising incidence and prevalence of allergic disorders is expected to aid in the growth of the global allergy immunotherapy market.
For instance, according to the Centers for Disease Control and Prevention, the U.S. recorded 19.2 million and 5.2 million cases of hay fever in adults aged 18 and over and children under age 18 years, respectively, in 2018.
Moreover, the changes in environmental conditions and increasing pollution are driving the global allergy immunotherapy market growth. For instance, according to the Asthma and Allergy Foundation of America (AAFA), about 23 million people in the U.S. have symptoms from ragweed pollen allergy. These symptoms can make life depressed for those with allergies, which can also cause asthma symptoms for allergic asthma people.
|Base Year:||2021||Market Size in 2022:||US$ 2,116.0 Mn|
|Historical Data for:||2017 to 2021||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||9.3%||2030 Value Projection:||US$ 4,312.6 Mn|
Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Allergopharma, HAL Allergy Group, Aimmune Therapeutics, DBV Technologies, Leti Pharma, and Jubilant HollisterStier
|Restraints & Challenges:||
Figure 2. Global Allergy Immunotherapy Market Share (%), by Distribution Channel, 2022
Global Allergy Immunotherapy Market: Restraint
The lack of awareness among patients about allergy immunotherapy is expected to restrain growth of the global allergy immunotherapy market. Additionally, side effects associated with allergic immunotherapy is another factor that is predicted to restrict the market growth.
Global Allergy Immunotherapy Market - Impact Analysis of COVID-19
The COVID-19 outbreak has adversely affected the allergy immunotherapy market. It has become difficult for the researchers to conduct researches during this COVID-19 pandemic. People with ragweed pollen allergy are getting confused with the COVID-19 symptoms as the symptoms associated with both conditions are similar. Thus, the overall market is estimated to observe an optimistic growth during the COVID-19 pandemic.
Major players operating in the global allergy immunotherapy market include Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Allergopharma, HAL Allergy Group, Aimmune Therapeutics, DBV Technologies, Leti Pharma, and Jubilant HollisterStier.
Immunotherapy is a preventive treatment for allergic reaction to substance such as grass pollens, house dust mites, and bee venom.
Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT) are the immunotherapies used for the treatment of allergic rhinitis, allergic asthma, food allergy, venom allergy, and other allergies.
Subcutaneous immunotherapy (SCIT) is the most commonly used and effective form allergy immunotherapy.
The global allergy immunotherapy market is expected to witness significant growth over the forecast period, owing to increasing approval of allergy immunotherapy by regulatory authority.
For instance, in 2017, ALk, a pharmaceutical company focusing on prevention, treatment, and diagnosis of allergy, received the U.S. Food and Drug Administration Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet Acarizax.
Furthermore, the tablet is also approved in Europe for the indication of house dust mite (HDM) for adults 18 through 65 years of age under the brand name Acarizax.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.